Cancer Immunotherapy: Urothelial Cancer Source: Society for Immunotherapy of Cancer

Cancer Immunotherapy: Urothelial Cancer Source: Society for Immunotherapy of Cancer https://reference.medscape.com/cc2/p10/sitc-urothelial-cancer-immunotherapy-2025a10000i6?ecd=WNL_drugguide_260203_MSCPREF_onc_etid8073926&uac=148436CN&impID=8073926 In October 2024, the Society for Immunotherapy of Cancer (SITC) published an update to its 2021 clinical practice guideline on immunotherapy for the treatment of urothelial cancer to provide evidence- and consensus-based recommendations to inform healthcare professionals on important aspects of immunotherapeutic treatment of urothelial cancer. This Medscape guideline summary includes recommendations on diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QoL) considerations, and is intended for oncologists working in secondary care. This summary includes updates to the guideline to reflect new evidence and changes to the approval status of and indications for some of the treatments discussed.